Skip to content

Impact of Tear Substitute Use on Dry Eye in Gamers.

Dry Eye and Digital Asthenopia Signs and Symptoms in Gaming Adults. Impact of Tear Substitute Use.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05536661
Acronym
HYAGAME
Enrollment
56
Registered
2022-09-13
Start date
2019-07-04
Completion date
2019-07-07
Last updated
2022-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaporative Dry Eye

Brief summary

Clinical, prospective, comparative, controlled, single-blind study, on the signs and symptoms of dry eye before and after 3 days of playing video games with the use of artificial tears (Hyabak) versus no intervention.

Detailed description

Adult attendees to a Gamers convention will complete questionnairs and undergo an opthalmological evaluation before and after playing for 3 days in a row. Participants will be randomized into 2 groups of equal size: 1. Study group. 2. Control group. The Study group will instill hyaluronic acid 0.15% artificial tears in both eyes 4 times a day during the 3 days of the video game session, while the control group will not instill artificial tears.

Interventions

OTHERPreservative free hyaluronic acid artificial tear

Ocular lubricant

Sponsors

Crossdata
CollaboratorUNKNOWN
Laboratorios Thea, Spain
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* 18 years or older * Participants in videogame convention planning to play video games for a minimum of 6 hours daily for the next 3 days. * Voluntarily accept to participate and sign informed consent form

Exclusion criteria

* Ocular, nasolagrimal or palpebral active condition different from dry eye disease. * History of ocular trauma or infecction in the last 3 months previous to inclusion. * History of refractive surgery. * Visual acuity 0.5 or less in at least 1 eye. * Ocular medication use in the 3 days prior to inclusion. * History of systemic condition asociated to dry eye. * Use of systemic medication known to induce dry eye in the last 30 days. * Known allergy to hyaluronic acid. * Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frameDescription
Standard Patient Evaluation of Eye Dryness (SPEED)Between Day 1 and Day 3Change in Standard Patient Evaluation of Eye Dryness (SPEED) score between study and control group (range 0-28, with higher scores indicative of dry eye disease symptoms)

Secondary

MeasureTime frameDescription
Tear Breakup Time (TBUT)Between Day 1 and Day 3Change in Tear Breakup Time (TBUT) score (normal values \> or equal to 10 seconds) between study and control group
Conjunctival staining with lisamine green measured with Oxford scaleBetween Day 1 and Day 3Change in conjunctival oxford staining score (range 0-5 with higher scores indicative of more staining) between study and control group
Corneal staining with fluorescein measured with Oxford scaleBetween Day 1 and Day 3Change in corneal oxford staining score (range 0-5 with higher scores indicative of more staining) between study and control group
Conjunctival hyperemia measured with McMonnies Chapman scaleBetween Day 1 and Day 3Change in McMonnies Chapman score (range 0-5, with higher scores indicative of more conjunctival hyperemia) between study and control group
Near convergence measured with a RAF binocular gaugeBetween Day 1 and Day 3Change in near convergence between study and control group
Accomodation distance measured with a RAF binocular gaugeBetween Day 1 and Day 3Change in accomodation distance between study and control group
Schirmer I tear volume testBetween Day 1 and Day 3Change in Schirmer score (normal values equal or higher than 10) between study and control group

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026